Anika Therapeutics (STU:AKP) Research & Development: €22.71 Mil (TTM As of Mar. 2026)


STU:AKP Anika Therapeutics Inc STU:AKP
66 GF Score
Price €13.00
GF Value €17.79
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Anika Therapeutics Research & Development?

Anika Therapeutics STU:AKP -0.76% 66 Research & Development is €22.71 Mil as of Mar. 2026. GuruFocus rates STU:AKP with a GF Score™ of 66/100 and a GF Value™ of €17.79 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Anika Therapeutics's Research & Development for the three months ended in Mar. 2026 was €5.81 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €22.71 Mil.

Anika Therapeutics  (STU:AKP) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Anika Therapeutics Research & Development Related Terms

Anika Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Anika Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anika Therapeutics Research & Development Chart

Anika Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.18 17.30 19.96 24.40 22.01

Anika Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.61 5.47 5.92 5.51 5.81
STU:AKP
66GF Score
Anika Therapeutics Inc STU:AKP
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anika Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €22.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €22.71 Mil mean?
Anika Therapeutics (STU:AKP) has a Research & Development of €22.71 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Anika Therapeutics and its competitors.
Is Anika Therapeutics' Research & Development too high?
Anika Therapeutics' current Research & Development is €22.71 Mil. Overall, Anika Therapeutics has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Anika Therapeutics' Research & Development compare to LFCR and DERM?
Anika Therapeutics' Research & Development of €22.71 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Anika Therapeutics and its competitors. Anika Therapeutics's current Research & Development is €22.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anika Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Anika Therapeutics (STU:AKP) is currently considered Modestly Undervalued. The stock's GF Value™ is €17.79, compared to a current price of €13.00 — trading 26.9% below its estimated fair value. The current Research & Development is €22.71 Mil. Anika Therapeutics' overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Anika Therapeutics (STU:AKP), the current Research & Development is €22.71 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Anika Therapeutics (STU:AKP) Overvalued in 2026?

Based on GuruFocus' analysis, Anika Therapeutics stock appears to be undervalued. The current stock price of €13.00 is trading 26.9% below its estimated GF Value™ of €17.79. GuruFocus considers Anika Therapeutics to be Modestly Undervalued.

Key valuation signals for STU:AKP:

  • Research & Development: €22.71 Mil
  • GF Value™: €17.79 vs. price of €13.00 (26.9% below fair value)
  • GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the STU:AKP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Anika Therapeutics Business Description

Other Exchanges ANIK:USA
Address 32 Wiggins Avenue, Bedford, MA, USA, 01730
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
66GF Score

Get the complete analysis for STU:AKP

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.00
Price
€17.79
GF Value